Put companies on watchlist
M1 Kliniken AG
ISIN: DE000A0STSQ8
WKN: A0STSQ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

M1 Kliniken AG · ISIN: DE000A0STSQ8 · EQS - Company News (68 News)
Country: Germany · Primary market: Germany · EQS NID: 1145081
04 November 2020 08:00AM

M1 Kliniken AG: Number of treatments increase by almost 20 % in Q3-2020. Comprehensive hygiene concept ensures continuation of treatment activities.


DGAP-News: M1 Kliniken AG / Key word(s): 9 Month figures/Expansion
M1 Kliniken AG: Number of treatments increase by almost 20 % in Q3-2020. Comprehensive hygiene concept ensures continuation of treatment activities.

04.11.2020 / 08:00
The issuer is solely responsible for the content of this announcement.



M1 Kliniken AG: Number of treatments increase by almost 20% in Q3-2020. Comprehensive hygiene concept ensures continuation of treatment activities.

Berlin, 4.11.2020 - In contrast to the worsening pandemic situation, M1 Kliniken AG continues to record strong demand. The number of injection treatments and surgical treatments performed in the German market in the 3rd quarter of 2020 rose by almost 20% year-on-year to over 65,000. The international locations are also expanding their market position and were able to significantly increase the number of treatments. In the 3rd quarter of 2020, a further practice was opened in Austria (Graz).

M1 Kliniken AG expects the positive development to continue in the 4th quarter 2020. To date, the company is not affected by the current lock-down arrangements and treatments will continue on the basis of a comprehensive hygiene concept. The Australian centers resumed operations at the end of October after a lock-down of more than three months. The high expectations for the restart were more than exceeded. In addition, the first practice in Eastern Europe (Zagreb/Croatia) was opened at the end of October 2020.

For the further expansion of the practice network, M1 Kliniken AG is closely monitoring the local pandemic developments. For the time being, no further international projects will be started and a sustained decline in the number of corona cases will be awaited. In the German market, four new locations are currently being developed in cities without M1 presence. M1 is also recruiting new doctors to further expand treatment capacities.

In addition, M1 has been involved in COVID19 testing since mid-year. Between July and October 2020, more than 25,000 test samples have been taken for corporate customers. A first COVID test centre in Berlin for "walk-in testing" as a prototype for further locations in Germany was opened in early November 2020.

About M1 Kliniken AG
M1 Kliniken AG is the leading provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brands M1 Med Beauty, beauty medical treatments are currently offered at more than 35 locations. The 'M1 Schlossklinik' for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with its international expansion and is currently active in Austria, the Netherlands and Australia. The Group is now also growing in other European countries and markets high-quality products to private customers, doctors, pharmacies and wholesalers under the M1 Select and M1 Aesthetics brands.




Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


04.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: ir@m1-kliniken.de
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart, Tradegate Exchange
EQS News ID: 1145081

 
End of News DGAP News Service

1145081  04.11.2020 

fncls.ssp?fn=show_t_gif&application_id=1145081&application_name=news&site_id=boersengefluester_html
Visual performance / price development - M1 Kliniken AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.